Abstract PS5-01-02: Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer: long-term survival results from the phase 3 PHILA study
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Zhengzhou University, Henan Cancer Hospital, First Hospital of Jilin University, Central South University, Hunan Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, First Hospital of China Medical University, China Medical University, Shandong Tumor Hospital, Sun Yat-sen University Cancer Center, Hebei Medical University, Fourth Hospital of Hebei Medical University, Sichuan University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, Guangxi Medical University, First Affiliated Hospital of GuangXi Medical University, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Chongqing University, Liaoning Cancer Hospital & Institute, Tumor Hospital of Guangxi Medical University, University of Science and Technology of China, Jilin Province Tumor Hospital, Wuhan Union Hospital, Huazhong University of Science and Technology, Henan University of Science and Technology, Zhejiang Cancer Hospital, First Affiliated Hospital of Henan University of Science and Technology, First Affiliated Hospital of Xi'an Jiaotong University, Hubei Cancer Hospital, Peking University Cancer Hospital, Nanfang Hospital, Southern Medical University, Jiangsu Hengrui Medicine (China)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129409936